5 Hot Stocks to Trade
Once a Covid lockdown favorite, Zoom Communications (ZM) is the first stock to watch today. The company posted first-quarter results after markets closed.Zoom grew revenue by 2.6% Y/Y to $1.17 billion. It earned $1.43 per share. In Q2, Zoom expects revenue of up to $1.2 billion. For the year, it expects to earn between $5.56 and $5.59 a share.Watch out for the market’s reaction to TD Bank (TD) in its fiscal Q2 results posted this morning. The market may not react to its net interest income and provision for credit loss results.At number three, Canada Goose (GOOS) is a good trade. GOOS stock gained 19.62% after posting direct-to-consumer sales growth of 15.7% to $314.1 million. It reduced its capital expenditures and eliminated its stock buyback. Debt fell by 30% while cash rose.XPeng (XPEV) is stock #4. For the first time in its history, it almost earned a profit in the first quarter. After gross margin was 15.6%, a record, it lost just $0.04 a share.At #5, Lumen Technologies (LUMN) will rise by at least 10% today. AT&T (T) is buying its fiber business for $5.75 billion. This is a good deal for AT&T. Lumen will continue with its turnaround plan.As for stocks to avoid, beware of Wolfspeed (WOLF). The media reported rumors of the company filing for bankruptcy. WOLF stock traded as low as $0.82 on Wednesday, ending the day at $1.28. The stock once traded at over $100 in 2022.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


